Current statistics indicate that hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide and the third leading cause of cancer-related death. Major predisposing conditions are hepatitis B virus (HBV) and hepatitis C virus (HCV) infections. To date treatment approach includes liver transplantation, surgical resection and or ablation, however; recurrence, metastasis, and mortality still remains high. Therefore, alternative treatments such as gene therapy is increasingly being considered as a feasible proposal. In this mini review we will focus on novel data of the past 10 years on the subject of gene therapy and hepatocellular carcinoma.
No takes yet. Share an insight, caveat, or question.
Kosmıdis et al. (2019) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: